FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy ...

Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration, FDA, has cleared the IND for the IRAK4 degrader ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer ...

Oregon State University researchers have discovered a way to get anti-inflammatory medicine across the blood-brain barrier, ...

The company outlined its strategic focus on the IRAK4 program, emphasizing opportunities in hematological malignancies like Non-Hodgkin's Lymphoma (NHL) and Acute Myeloid Leukemia (AML).

Human TLRs and/or interleukin-1 receptors (IL-1Rs) have been implicated in host defence by the discovery of IL-1R-associated kinase 4 (IRAK4) deficiency in children with bacterial diseases ...

“GS-6791/NX-0479 is a highly optimized, selective, oral degrader of IRAK4, a master regulator of IL-1R/TLR signaling pathways that plays a crucial role in inflammatory processes. IRAK4 has both ...

The company outlined its strategic focus on the IRAK4 program, emphasizing opportunities in hematological malignancies like Non-Hodgkin’s Lymphoma (NHL) and Acute Myeloid Leukemia (AML). Curis ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer ...